Sudarshan Pharma Industries (543828) Q1 26/27 earnings summary

Executive summary

• Unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, were approved and reviewed without qualification by the auditors.

• The company operates in the specialty chemicals sector, with activities in API manufacturing, jobwork, and chemical trading.

Financial highlights

• Standalone revenue from operations for Q1 FY27 was ₹16,566.03 lakhs, up from ₹14,231.10 lakhs year-over-year but down from ₹19,980.98 lakhs sequentially.

• Standalone net profit for the quarter was ₹604.18 lakhs, compared to ₹373.28 lakhs in Q1 FY26 and ₹954.28 lakhs in Q4 FY26.

• Consolidated revenue from operations for Q1 FY27 was ₹17,441.84 lakhs, up from ₹14,526.16 lakhs year-over-year but down from ₹22,092.13 lakhs sequentially.

• Consolidated net profit attributable to owners was ₹585.52 lakhs, compared to ₹403.67 lakhs in Q1 FY26 and ₹1,072.62 lakhs in Q4 FY26.

• Basic and diluted EPS (standalone) for the quarter were ₹0.25, up from ₹0.15 year-over-year.

Outlook and guidance

• Closure of the Palghar manufacturing unit is expected to rationalize costs and focus resources on more profitable operations.